King Pharmaceuticals begins phase 2 trial of MRE0094 for diabetic foot ulcers

By Lisa Kerner

Erie, Pa., - King Pharmaceuticals began its phase 2 clinical trial program evaluating the safety and efficacy of its topical investigational drug MRE0094 in patients with chronic, neuropathic, diabetic foot ulcers.

"We are very excited about the potential of MRE0094 as a safe and effective treatment for chronic, neuropathic, diabetic foot ulcers," stated Michael K. Jolly, executive vice president, research and development, of King, in a news release.

"During the course of our phase 1 study in patients with this condition, we observed no safety issues related to MRE0094 and noted positive effects on the rate of wound closure."

MRE0094 is an adenosine A2A receptor agonist that favorably affects the inflammation associated with these ulcers by regulating the response of inflammatory cells and mediators, and by enhancing the tissue proliferation phase of wound healing, according to King.

Diabetes is a major U.S. health concern affecting more than 6% of the population, according to Jolly, with approximately 1.3 million newly diagnosed cases annually. It is estimated that approximately 15% of diabetic patients will develop foot ulceration during the course of their disease.

King Pharmaceuticals, headquartered in Bristol, Tenn., is a vertically integrated branded pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.